Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Update

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) saw a significant decline in short interest in March. As of March 31st, there was short interest totalling 3,660,000 shares, a decline of 17.6% from the March 15th total of 4,440,000 shares. Currently, 10.6% of the shares of the company are sold short. Based on an average daily volume of 426,500 shares, the days-to-cover ratio is presently 8.6 days.

Y-mAbs Therapeutics Trading Up 3.3 %

YMAB opened at $4.69 on Monday. Y-mAbs Therapeutics has a 12 month low of $3.86 and a 12 month high of $17.78. The business’s 50-day moving average price is $5.06 and its 200-day moving average price is $8.45. The company has a market cap of $212.07 million, a P/E ratio of -8.69 and a beta of 0.71.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The company had revenue of $26.50 million during the quarter, compared to the consensus estimate of $26.70 million. During the same quarter in the previous year, the firm posted ($0.02) EPS. Equities research analysts forecast that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on YMAB. HC Wainwright reduced their price target on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Truist Financial reduced their target price on Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, March 5th. Bank of America lowered their price target on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Wednesday, March 5th. Morgan Stanley lowered their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research note on Wednesday, March 5th. Finally, Wedbush reissued an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $18.30.

Insider Activity

In other news, insider Thomas Gad sold 10,810 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the transaction, the insider now directly owns 202,721 shares in the company, valued at approximately $1,060,230.83. This trade represents a 5.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Paradigm Biocapital Advisors LP raised its stake in shares of Y-mAbs Therapeutics by 3.7% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company’s stock valued at $33,171,000 after acquiring an additional 150,000 shares during the last quarter. Acorn Capital Advisors LLC bought a new position in Y-mAbs Therapeutics during the 4th quarter valued at approximately $22,408,000. Caligan Partners LP lifted its holdings in Y-mAbs Therapeutics by 47.9% in the 4th quarter. Caligan Partners LP now owns 1,767,982 shares of the company’s stock worth $13,843,000 after buying an additional 572,729 shares during the period. State Street Corp grew its position in shares of Y-mAbs Therapeutics by 50.4% in the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after buying an additional 405,169 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Y-mAbs Therapeutics by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 822,309 shares of the company’s stock valued at $6,440,000 after buying an additional 8,820 shares during the period. Hedge funds and other institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.